Bicarbonate supplementation as a preventive way in statins-induced muscle damage

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 11, Issue 1, 2008, Pages 1-8

  Kobayashi, Masaki ^a   Kagawa, Toshiki ^a   Narumi, Katsuya ^a   Itagaki, Shirou ^a   Hirano, Takeshi ^a   Iseki, Ken ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; CASPASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANIMAL; ARTICLE; CELL CULTURE; CELL SURVIVAL; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; MALE; METABOLISM; MUSCLE DISEASE; MYOBLAST; PHYSIOLOGY; RAT; WISTAR RAT;

ANIMALS; BICARBONATES; CASPASES; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MUSCULAR DISEASES; MYOBLASTS; RATS; RATS, WISTAR; SODIUM BICARBONATE;

EID: 53549133372     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j33018     Document Type: Article

References (22)

1. Havel, R.J., Rapaport, E., Management of primary hyperlipidemia. New Engl J Med,332:1491-1498, 1995.
2. Jukema, J.W., Bruschke, A.V., van Boven, A.J., Reiber, J.H., Bal, E.T., Zwinderman, A.H., Jansen, H., Boerma, G.J., van Rappard F.M., Lie, K.I. et al., Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation, 91:2528-2540, 1995.
3. Downs, J.R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D.R., Beere, P.A., Langendorfer, A., Stein, E.A., Kruyer, W., Gotto, A.M. Jr., Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA, 279:1615-1622, 1998.
4. Omar, M.A., Wilson, J.P., Cox, T.S., Rhabdomyolysis and HMG-CoA reductase Inhibitors. Ann Pharmacother, 35:1096-1107, 2001.
5. Pedersen, T.R., Kjekshus, J., Berg, K., Haghfelt, T., Faergeman, O., Faergeman, G., Pyorala, K., Miettinen, T., Wilhelmsen, L., Olsson, A.G., Wedel, H., Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) 1994. Atheroscler Suppl, 5:81-87, 2004.
6. Garnett, W.R., Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health Syst Pharm, 52: 1639-1645, 1995.
7. Maron, D.J., Fazio, S., Linton, M.F., Current perspectives on statins. Circulation, 101:207-213, 2000.
8. Guijarro, C., Blanco-Colio, L.M., Massy, Z.A., O'Donnell, M.P., Kasiske, B.L., Keane, W.F., Egido, J., Lipophilic statins induce apoptosis of human vascular smooth muscle cells. Kidney Int, 71:88-91, 1999.
9. Newton, C.J., Ran, G., Xie, Y.X., Bilko, D., Burgoyne, C.H., Adams, I., Abidia, A., McCollum, P.T., Atkin, S.L., Statin-induced apoptosis of vascular endothelial cells is blocked by dexamethasone. J Endocrinol, 174:7-16, 2002.
10. Ogata, Y., Takahashi, M., Takeuchi, K., Ueno, S., Mano, H., Ookawara, S., Kobayashi, E., Ikeda, U., Shimada, K., Fluvastatin induces apoptosis in rat neonatal cardiac myocytes: a possible mechanism of statin-attenuated cardiac hypertrophy. J Cardiovasc Pharmacol, 40:907-915, 2002.
11. Kobayashi, M., Kaido, F., Kagawa, T. Itagaki, S., Hirano, T., Iseki, K., Preventive effects of bicarbonate on cerivastatin-induced apoptosis. Int J Pharm, 341:181-188, 2007.
12. Kobayashi, M., Otsuka, Y., Itagaki, S., Hirano, T., Iseki, K., Inhibitory effects of statins on human monocarboxylate transporter 4. Int J Pharm, 317:19-25, 2006.
13. Itoh, T., Itagaki, S., Sasaki, K., Hirano, T., Takemoto, I., Iseki, K., Pharmacokinetic modulation of irinotecan metabolites by sulfobromophthalein. J Pharm Pharmacol, 56:809-812, 2004.
14. Kobayashi, M., Itagaki, S., Hirano, T., Iseki, K., Mechanism of L-lactic acid transport in L6 skeletal muscle cells. Drug Metab Pharmacokinet, 19:363-368, 2004.
15. Mosmann, T., Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods, 65:55-63, 1983.
16. Ferri, K.F., Kroemer, G., Organelle-specific initiation of cell death pathways. Nat Cell Biol, 3:255-263, 2001.
17. Salvesen, G.S., Dixit, V.M., Caspases: intracellular signaling by proteolysis. Cell, 91:443-446, 1997.
18. Thornberry, N.A., Lazebnik, Y., Caspases: enemies within. Science, 281:1312-1316, 1998.
19. Kobayashi, M., Fujita, I., Itagaki, S., Hirano, T. Iseki, K., Transport mechanism for L-lactic acid in human myocytes using human prototypic embryonal rhabdomyosarcoma cell line (RD cells). Biol Pharm Bull, 28:1197-1201, 2005.
20. Pierno, S., De Luca, A., Tricarico, D., Roselli, A., Natuzzi, F., Ferrannini, E., Laico, M., Camerino, D.C., Potential risk of myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers. J Pharmacol Exp Ther, 275:1490-1496, 1995.
21. Pierno, S., De Luca, A., Liantonio, A., Camerino, C., Conte Camerino, D., Effects of HMG-CoA reductase inhibitors on excitation-contraction coupling of rat skeletal muscle. Eur J Pharmacol, 364:43-48, 1999.
22. Smith, P.F., Eydelloth, R.S., Grossman, S.J., Stubbs, R.J., Schwartz, M.S., Germershausen, J.I., Vyas, K.P., Kari, P.H., MacDonald, J.S., HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies, J Pharmacol Exp Ther, 257:1225-1235, 1991.